The drug, which garnered national attention in March when it was touted by President Donald Trump, has been a subject of scrutiny as conflicting studies emerge on its efficacy in treating COVID-19. Small studies suggesting the drug could be a helpful treatment for the disease have been outweighed by larger studies revealing evidence that the drug was not effective and caused heart problems in some COVID-19 patients.
WHO’s announcement comes two days after the FDA rescinded its emergency use authorization for hydroxychloroquine and chloroquine, citing the same reasons as WHO.
More articles on practice management:
New York neurosurgeon featured in Netflix docuseries ‘Lenox Hill’
Where Medtronic’s 2nd-largest segment is doubling down — 5 VP insights
California hospital acquires endoscopic spine surgery system
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
